Seroatlas · Human Serome Atlas

TRIP12

E3 ubiquitin-protein ligase TRIP12

Also known as: KIAA0045, TRIPC, TRIPC_HUMAN, ULF

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q14669
Gene: TRIP12
Ensembl: ENSG00000153827
Chromosome: 2
Canonical length: 1992 aa
Protein class: Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins
Subcellular location: Nuclear speckles

OverviewNCBI Gene

The protein encoded by this gene is an E3 ubiquitin-protein ligase involved in the degradation of the p19ARF/ARF isoform of CDKN2A, a tumor suppressor. The encoded protein also plays a role in the DNA damage response by regulating the stability of USP7, which regulates tumor suppressor p53. [provided by RefSeq, Jan 2017]

Canonical amino-acid sequenceUniProt

1992 residues, UniProt reviewed canonical sequence.

>Q14669|TRIP12
     1  MSNRPNNNPG GSLRRSQRNT AGAQPQDDSI GGRSCSSSSA VIVPQPEDPD RANTSERQKT
    61  GQVPKKDNSR GVKRSASPDY NRTNSPSSAK KPKALQHTES PSETNKPHSK SKKRHLDQEQ
   121  QLKSAQSPST SKAHTRKSGA TGGSRSQKRK RTESSCVKSG SGSESTGAEE RSAKPTKLAS
   181  KSATSAKAGC STITDSSSAA STSSSSSAVA SASSTVPPGA RVKQGKDQNK ARRSRSASSP
   241  SPRRSSREKE QSKTGGSSKF DWAARFSPKV SLPKTKLSLP GSSKSETSKP GPSGLQAKLA
   301  SLRKSTKKRS ESPPAELPSL RRSTRQKTTG SCASTSRRGS GLGKRGAAEA RRQEKMADPE
   361  SNQEAVNSSA ARTDEAPQGA AGAVGMTTSG ESESDDSEMG RLQALLEARG LPPHLFGPLG
   421  PRMSQLFHRT IGSGASSKAQ QLLQGLQASD ESQQLQAVIE MCQLLVMGNE ETLGGFPVKS
   481  VVPALITLLQ MEHNFDIMNH ACRALTYMME ALPRSSAVVV DAIPVFLEKL QVIQCIDVAE
   541  QALTALEMLS RRHSKAILQA GGLADCLLYL EFFSINAQRN ALAIAANCCQ SITPDEFHFV
   601  ADSLPLLTQR LTHQDKKSVE STCLCFARLV DNFQHEENLL QQVASKDLLT NVQQLLVVTP
   661  PILSSGMFIM VVRMFSLMCS NCPTLAVQLM KQNIAETLHF LLCGASNGSC QEQIDLVPRS
   721  PQELYELTSL ICELMPCLPK EGIFAVDTML KKGNAQNTDG AIWQWRDDRG LWHPYNRIDS
   781  RIIEQINEDT GTARAIQRKP NPLANSNTSG YSESKKDDAR AQLMKEDPEL AKSFIKTLFG
   841  VLYEVYSSSA GPAVRHKCLR AILRIIYFAD AELLKDVLKN HAVSSHIASM LSSQDLKIVV
   901  GALQMAEILM QKLPDIFSVY FRREGVMHQV KHLAESESLL TSPPKACTNG SGSMGSTTSV
   961  SSGTATAATH AAADLGSPSL QHSRDDSLDL SPQGRLSDVL KRKRLPKRGP RRPKYSPPRD
  1021  DDKVDNQAKS PTTTQSPKSS FLASLNPKTW GRLSTQSNSN NIEPARTAGG SGLARAASKD
  1081  TISNNREKIK GWIKEQAHKF VERYFSSENM DGSNPALNVL QRLCAATEQL NLQVDGGAEC
  1141  LVEIRSIVSE SDVSSFEIQH SGFVKQLLLY LTSKSEKDAV SREIRLKRFL HVFFSSPLPG
  1201  EEPIGRVEPV GNAPLLALVH KMNNCLSQME QFPVKVHDFP SGNGTGGSFS LNRGSQALKF
  1261  FNTHQLKCQL QRHPDCANVK QWKGGPVKID PLALVQAIER YLVVRGYGRV REDDEDSDDD
  1321  GSDEEIDESL AAQFLNSGNV RHRLQFYIGE HLLPYNMTVY QAVRQFSIQA EDERESTDDE
  1381  SNPLGRAGIW TKTHTIWYKP VREDEESNKD CVGGKRGRAQ TAPTKTSPRN AKKHDELWHD
  1441  GVCPSVSNPL EVYLIPTPPE NITFEDPSLD VILLLRVLHA ISRYWYYLYD NAMCKEIIPT
  1501  SEFINSKLTA KANRQLQDPL VIMTGNIPTW LTELGKTCPF FFPFDTRQML FYVTAFDRDR
  1561  AMQRLLDTNP EINQSDSQDS RVAPRLDRKK RTVNREELLK QAESVMQDLG SSRAMLEIQY
  1621  ENEVGTGLGP TLEFYALVSQ ELQRADLGLW RGEEVTLSNP KGSQEGTKYI QNLQGLFALP
  1681  FGRTAKPAHI AKVKMKFRFL GKLMAKAIMD FRLVDLPLGL PFYKWMLRQE TSLTSHDLFD
  1741  IDPVVARSVY HLEDIVRQKK RLEQDKSQTK ESLQYALETL TMNGCSVEDL GLDFTLPGFP
  1801  NIELKKGGKD IPVTIHNLEE YLRLVIFWAL NEGVSRQFDS FRDGFESVFP LSHLQYFYPE
  1861  ELDQLLCGSK ADTWDAKTLM ECCRPDHGYT HDSRAVKFLF EILSSFDNEQ QRLFLQFVTG
  1921  SPRLPVGGFR SLNPPLTIVR KTFESTENPD DFLPSVMTCV NYLKLPDYSS IEIMREKLLI
  1981  AAREGQQSFH LS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TRIP12 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.39
Highest tissue expression: 104 nTPM

Expression across tissuesHPA

Tissue

testis: 104 nTPM
skeletal muscle: 74 nTPM
thymus: 52 nTPM
tonsil: 52 nTPM
choroid plexus: 51 nTPM
bone marrow: 51 nTPM

Single-cell type

neutrophils: 702 nCPM
prostatic glandular cells: 513 nCPM
neutrophil progenitors: 466 nCPM
pituicytes/fscs: 390 nCPM
monocytes: 306 nCPM
adrenal cortex cells: 289 nCPM

Immune cell

neutrophil: 34 nTPM
basophil: 34 nTPM
eosinophil: 20 nTPM
T-reg: 17 nTPM
non-classical monocyte: 15 nTPM
intermediate monocyte: 14 nTPM

Brain region

cerebral cortex: 120 nTPM
white matter: 103 nTPM
basal ganglia: 95 nTPM
midbrain: 94 nTPM
medulla oblongata: 93 nTPM
pons: 93 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about TRIP12.

Disease | AllUniProt

Conditions TRIP12 is implicated in, by any mechanism.

Clark-Baraitser syndrome (CLABARS) MIM:617752

Disease | GeneticClinVar

100 pathogenic / likely-pathogenic of 695 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.06
gnomAD pLI: 1
gnomAD missense Z: 4.64
DepMap mean gene effect: -0.19
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

HECT domain
WWE domain
Armadillo-like helical
Armadillo-type fold
HECT, E3 ligase catalytic domain
WWE domain superfamily
E3 ubiquitin-protein ligase HECTD1/TRIP12-like
HECT-domain (ubiquitin-transferase)
E3 ubiquitin-protein ligase TRIP12-like, TPR repeats
E3 ubiquitin-protein ligase TRIP12-like, TPR repeats

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of TRIP12 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TRIP12 as an antibody target. Whether an autoantibody or antibody against TRIP12 could matter depends on whether native TRIP12 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TRIP12 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label TRIP12 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...